Diamond Hill Capital Management LLC Investment Advisor Acquires New Position in uniQure N.V. $QURE

Posted by Francis Steltz on Aug 18th, 2026

Diamond Hill Capital Management LLC Investment Advisor bought a new position in uniQure N.V. (NASDAQ:QURE – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 17,463 shares of the biotechnology company’s stock, valued at approximately $804,000.

Several other large investors also recently made changes to their positions in QURE. Torren Management LLC bought a new stake in shares of uniQure during the 4th quarter worth about $28,000. IFP Advisors Inc acquired a new stake in shares of uniQure during the fourth quarter worth $48,000. Smartleaf Asset Management LLC purchased a new stake in uniQure during the fourth quarter valued at about $48,000. CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 906 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on QURE. Wells Fargo & Company increased their target price on shares of uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Royal Bank Of Canada boosted their target price on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a report on Wednesday, June 17th. Mizuho increased their price objective on uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research note on Tuesday, May 5th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

Check Out Our Latest Stock Analysis on uniQure

uniQure Price Performance

uniQure stock opened at $47.97 on Tuesday. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -11.96 and a beta of 0.93. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The business’s 50-day simple moving average is $41.68 and its 200 day simple moving average is $28.04.

uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same period last year, the firm earned ($0.69) earnings per share. As a group, research analysts anticipate that uniQure N.V. will post -3.74 earnings per share for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, insider Walid Abi-Saab sold 30,000 shares of uniQure stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the sale, the insider directly owned 148,235 shares in the company, valued at approximately $6,881,068.70. The trade was a 16.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 164,429 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer directly owned 558,810 shares in the company, valued at $24,766,459.20. This trade represents a 22.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 388,229 shares of company stock valued at $16,817,099 in the last 90 days. 4.65% of the stock is currently owned by corporate insiders.

uniQure Company Profile

(Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.